Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genetic Signatures Ltd. ( (AU:GSS) ) has provided an update.
Genetic Signatures Limited announced a change in the director’s interest, with Anne Lockwood acquiring 250,000 Restricted Rights as approved at the company’s Annual General Meeting. This change reflects the company’s ongoing commitment to align its leadership’s interests with its strategic goals, potentially impacting its governance and stakeholder relations positively.
The most recent analyst rating on (AU:GSS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures Limited operates in the biotechnology industry, focusing on the development and commercialization of molecular diagnostic solutions. The company specializes in providing innovative products for the detection of infectious diseases, leveraging its proprietary 3base technology to enhance the speed and accuracy of pathogen detection.
Average Trading Volume: 163,312
Technical Sentiment Signal: Sell
Current Market Cap: A$68.14M
See more insights into GSS stock on TipRanks’ Stock Analysis page.